Non-exclusive Diclofenac Discount Agreement
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Diclofenac (ATC-Code nach WHO: D11AX18)
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No guaranteed demand; actual revenue may be minimal or zero.
Early termination risk if exclusive agreements are signed by buyer.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Aug 31, 2027
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Aug 2027
- Supply of Diclofenac-containing medicinal products (ATC D11AX18) under non-exclusive rebate agreements
- Adherence to predefined contract terms (no individual negotiation)
Show full summary
Non-exclusive pharmaceutical discount agreement under Open House model for Diclofenac (ATC D11AX18) with AOK PLUS for Saxony and Thuringia. Any interested pharmaceutical company meeting conditions can join during participation period. No guaranteed volumes, no exclusivity. Contract ends 31.08.2027 regardless of start date.
Risks
No guaranteed demand; actual revenue may be minimal or zero.
Early termination risk if exclusive agreements are signed by buyer.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur as defined in § 4(18) AMG for the offered medicinal products
Eligibility
- No exclusion grounds under §§ 123, 124 GWB (submit self-declaration)
Administrative
- Compliance with Russia sanctions (EU Regulation 833/2014) via self-declaration
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive Diclofenac Discount Agreement
Open House model for concluding non-exclusive rebate agreements under § 130a Abs. 8 SGB V for Diclofenac. No minimum quantities, no exclusive supply. Participation open to all eligible pharmaceutical companies. Contract ends 31.08.2027.
Location
Duration
Category
Award Criteria
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Diclofenac (ATC-Code nach WHO: D11AX18)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 14 Jul 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 460732-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No guaranteed demand; actual revenue may be minimal or zero.
Early termination risk if exclusive agreements are signed by buyer.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications